Genome editing with #CRISPR is the most important life science breakthrough of our time. It's a B.C. and A.C. We interviewed @WalterIsaacson about his new book, THE CODE BREAKER, which is a masterpiece medscape.com/viewarticle/95…
w/ transcript /1
We started the conversation reading 2 key passages that convey the significance of #CRISPR /2
And this one /3
The book is not just about @doudna_lab and other protagonists, such as @zhangf@geochurch@EricLander46, Emmanuelle Charpentier, but thru the perspective of grad students and post docs and about team science /4
There is substantial emphasis on the power of basic science, curiosity and creativity, and not just the linear model of discovery.
"They were doing it purely out of curiosity, like Leonardo da Vinci" /5
The links to the computer, digital, coding parallel advances are striking. Everything from the Homebrew Computer Club, the Asilomar conferences (there has been one for #AI), patent fights over chips, 0|1 vs ACGT, and so much more /6
Isaacson does a wonderful job differentiating germline editing, such as the reckless #CRISPR Babies work by Jiankui, to the remarkable progress in somatic editing @davidrliu@skathire /7
For me, the most heartwarming part of the book was he how brought Doudna and Charpentier back together again.
The infamous @Zoom get together /8
I asked Walter about the importance of scientists playing a role in public policy, since that certainly was not Jennifer Doudna's background. His response is remarkably insightful (not shown here) /9
On the democratization of #CRISPR, Isaacson takes a bit of a contrarian view (from the life science community) in supporting the DIY work of @4LOVofScience /10
Both @cuttingforstone and I were so deeply impressed with how lucid he made such a complex topic & into a veritable page turner. I can't recommend it enough fo anyone wanting to learn more about this breakthrough— it will have transformative impact in medicine and science
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…
3 New #LongCovid reports 1. Vaccination protection—1 dose 21%, 2 doses 59%, 3 doses 73% among ~590,000 people in Sweden (strong association) bmj.com/content/383/bm…
2. 3-year prospective follow up of a cohort of ~1350 participants, hospitalized in China
—Lung function restored back to baseline in most
—Higher risk of reinfection that people w/o Long Covid
—Half w/ persistent symptoms thelancet.com/journals/lanre…
3. At @RSNA annual meeting, brain MRI with microstructure imaging (DMI), participants with #LongCovid vs controls had microstructure changes associated with impaired cognition, sense of smell and fatigue eurekalert.org/news-releases/…
Big news #ESC2023 and @NEJM
In a placebo-controlled randomized trial of people with obesity + heart failure (with preserved ejection fraction). semaglutide (Wegovy) markedly improved symptoms, exercise time, reduced inflammatory markers (and weight loss) nejm.org/doi/full/10.10…
This also tells us something about the underlying mechanism of heart failure with preserved EF—metabolic dysfunction and attendant systemic inflammation—not previously acknowledged or confirmed
The accompanying editorial lays this finding out well. Prior studies of weight loss didn't help HFpEF